Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.63 USD
Change Today -0.07 / -1.23%
Volume 87.2K
As of 5:20 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

harvard bioscience inc (HBIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - $6.84
52 Week Low
10/1/14 - $4.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

harvard bioscience inc (HBIO) Related Businessweek News

No Related Businessweek News Found

harvard bioscience inc (HBIO) Details

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. The company offers syringe pumps and peristaltic pumps primarily under the Harvard Apparatus, Harvard Pumps, and KD Scientific brands, as well as component pumping modules; and lab equipment and supplies comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and AHN brands. It also provides spectrophotometers under the Libra, WPA, and BioDrop brands; microplate readers; amino acid analyzers; and gel electrophoresis equipment under the Hoefer and Scie-Plas brands. In addition, the company offers electroporation and electrofusion products under the Harvard Apparatus BTX brand; and cell electrophysiology products, such as equipment for patch clamp systems, amplifiers, data acquisition systems, bilayer workstations, temperature controllers, infusion chambers and accessories for imaging and recording, and multi-electrode arrays under the Warner Instrument, MCS, and HEKA brands. Further, it provides animal physiology products comprising instruments and accessories for tissue, organ, and animal based lab research, ranging from surgical products, infusion systems, microdialysis instruments, behavior research systems, isolated organ and tissue bath systems, bioreactors for regenerative medicine research, and in vivo electrophysiology recording and stimulation systems under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, and TBSI brands. It markets its products to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

417 Employees
Last Reported Date: 03/12/15
Founded in 1901

harvard bioscience inc (HBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $670.4K
Chief Financial Officer and Treasurer
Total Annual Compensation: $370.3K
Vice President of Strategic Marketing & Busin...
Total Annual Compensation: $260.1K
Vice President of Global Sales
Total Annual Compensation: $210.5K
Compensation as of Fiscal Year 2014.

harvard bioscience inc (HBIO) Key Developments

Harvard Bioscience Inc.(NasdaqGM:HBIO) added to Russell 2000 Index

Harvard Bioscience Inc. will be added to Russell 2000 Index

Harvard Bioscience Inc.(NasdaqGM:HBIO) added to Russell 3000 Index

Harvard Bioscience Inc. will be added to the Russell 3000 Index.

Harvard Bioscience Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter March 31, 2015; Provides Earnings Guidance for the Full Year of 2015

Harvard Bioscience Inc. announced unaudited consolidated earnings results for the first quarter March 31, 2015. For the quarter, the company reported revenues of $25,763,000 against $25,893,000 a year ago. Operating loss was $1,150,000 against operating profit of $1,334,000 a year ago. Loss before income taxes was $1,764,000 against income before income taxes of $1,019,000 a year ago. Net loss was $1,401,000 against net income of $719,000 a year ago. Diluted loss per common share was $0.04 against EPS of $0.02 a year ago. Net cash used in operating activities was $497,000 against cash flow from operating activities of $1,072,000 a year ago. Non-GAAP adjusted operating income was $960,000 against $2,706,000 a year ago. Non-GAAP adjusted net income was $756,000 against $1,688,000 a year ago. Non-GAAP adjusted diluted earnings per common share from continuing operations were $0.02 against $0.05 a year ago. The unfavorable year-to-year quarterly GAAP earnings comparison was due primarily to a decrease in revenues, costs to relocate and consolidate certain facilities, and higher acquisition costs. The unfavorable year-to-year quarterly non-GAAP earnings comparison was due primarily to a decrease in revenues and costs to relocate and consolidate certain facilities. Non-GAAP income from continuing operations was $0.8 million or $0.02 per diluted share compared to $1.7 million or $0.05 per diluted share in first quarter of last year. Revenues decreased $100,000 or 0.5% compared with revenues in the first quarter of last year. The negative impact for currency translation was $1.1 million and was due largely to the weakening euro relative to the U.S. dollar and in addition to negative currency translation, revenues were negatively impacted by lower sales from customers based in Europe of its U.S. produced products, compared with sales levels in the first quarter of last year. Capital expenditures were $1 million as compared to $781,000 for fourth quarter of last year. The increase in capital expenditures is due to investments in its infrastructure and ERP system as well as build outs related to the consolidation of the U.K. manufacturing facility, and the new Denville facility. The company is updating its financial guidance for the full year 2015 issued on February 26, 2015 to reflect the additional negative impact of foreign currency due to the strengthening of the U.S. dollar and the weaker-than-expected first quarter. The company expects revenues to be approximately $110 million to $112 million. Included in this guidance is the company's expectation that the negative impact of foreign currency will lower revenues by between $8 million and $10 million, based on current foreign currency exchange rates and lower demand experienced in first quarter. The company expects to report full-year 2015 non-GAAP diluted earnings per share of $0.21 to $0.23. This translates to GAAP diluted earnings per share of approximately $0.07 to $0.09. The company's expectation that it will incur costs of approximately $750,000 to $1 million, or approximately $0.02 per diluted share, on a non-GAAP basis, to relocate and consolidate certain manufacturing and distribution facilities in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HBIO:US $5.63 USD -0.07

HBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $143.22 USD +1.57
Bio-Rad Laboratories Inc $149.95 USD -0.66
Lonza Group AG SFr.127.80 CHF +2.90
PerkinElmer Inc $52.49 USD -0.15
Thermo Fisher Scientific Inc $130.82 USD +1.06
View Industry Companies

Industry Analysis


Industry Average

Valuation HBIO Industry Range
Price/Earnings 100.0x
Price/Sales 1.7x
Price/Book 2.1x
Price/Cash Flow 64.2x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARVARD BIOSCIENCE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at